Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Drug research gets NDDS-savvy
October 10, 2007
By: Soman Harachand
Contributing Writer, Contract Pharma
Designing novel delivery vehicles for off-patent molecules looks like a growing trend among Indian drug makers as therapeutics of ‘minimum toxicity with maximum efficacy’ turn increasingly vogue in the global marketplace. In January, Dabur Pharma launched a nanoscale drug delivery system (NDDS) for paclitaxel in India. This anti-cancer drug has been implicated in some undesirable side effects, largely owing to cremophor — a castor oil-based solvent used in its formulations. Dabur’s Nanoxel claims to cut this risk as it is cremophor free. Besides, polymeric nanoparticle drug delivery systems enable therapy to take a preferential course to the cancerous cells, thereby throwing open a larger window for anti-tumor activity, the company added. Specializing in delivery technologies for micellar delivery of hydrophobic drugs, this oncology firm is currently in late-stage clinical development of a peptide-based drug for gastrointestinal carcinomas. Liposomal drug delivery using biodegradable lipids is another area Dabur is keen on. New Delhi-based Dabur expects to take Nanoxel to regulated markets in coming years. In the U.S., it may compete with Abraxis Bio’s Abraxane, which uses human albumin for paclitaxel delivery. “While the efficacy of both products are comparable in terms of response rate, Nanoxel has been shown to be safer than Abraxane in terms of incidence of neuropathy, which is known dose limiting and cumulative toxicity of paclitaxel,” said sources from Dabur. Nano-enabled systems present a great promise as they are fast replacing polymer therapeutics. Growing at the rate of 37%, they are set to touch $26 billion by 2012 from the present $3.39 billion, predicts a report from Cientifica Ltd.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !